Institute of Biomedical Research (OTC: MRES), DBA M2Bio Sciences, has appointed a new member to its advisory board. A distinguished leader and financial and data analytics expert, Adrian Maizey brings a rich background to his new board member role. Maizey has worked with top-tier companies around the world in an array of industries, from the private-equity and hedge-fund spaces to private consumer-retail entities. Currently the CEO of Rand Capital Coffee, the exclusive licensee for Starbucks in Southern Africa, Maizey has also served in leadership positions, including as partner and chief financial, chief operating and chief compliance officer roles, in a number of prestigious financial and investment firms. The Institute of Biomedical Research is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence as well as evidence-based sustainable products and solutions, is sharing an update. “We are thrilled to have Adrian Maizey on board with us,” said M2Bio Sciences CEO Jeff Robinson in the press release. “His extensive experience in the financial and investment sectors, coupled with his outstanding leadership at Starbucks SA, make him an invaluable addition to our advisory board. Adrian’s insights and strategic acumen will undoubtedly play a pivotal role in propelling M2Bio Sciences to new heights. We look forward to working closely with him as we strive to revolutionize the biotechnology landscape.”
To view the full press release, visit https://ibn.fm/EsV2D
About the Institute of Biomedical Research Corp.
Institute of Biomedical Research, DBA M2Bio Sciences, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence (“AI”) as well as evidence-based sustainable products and solutions. The company develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx(TM), Medspresso(TM) and Liviana(TM) brands as well as AI-powered nutrition products and solutions under the M2Biome brand. In addition, the company’s research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. The company’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence. For more information about the company, please visit www.M2Bio.co.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork